Skip to content

Clinical Trial on Acupuncture Therapy in Patients With Gastrointestinal Neoplasms Laparoscopic Surgery

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02871245
Enrollment
120
Registered
2016-08-18
Start date
2016-09-21
Completion date
2017-07-31
Last updated
2017-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Neoplasms

Keywords

Acupuncture Therapy, Laparoscopic Surgery, Gastrointestinal Tract Recovery of Function

Brief summary

Patients accepted laparoscopic radical operation for carcinoma of colon and upper middle section of the rectum will be as the research object. Cancer patients are diagnosed based on pathology or cell biology. The trial is randomized, parallel and open. They are randomized into 2 groups: both groups receive surgery. The experimental group receives conventional treatment combine with electroacupuncture Zusanli point .etc finish operation and the contrast receives the same conventional treatment with experimental group. Clinical evaluation includes gastrointestinal tract recovery of function, pain relief, life quality improvement. Blood biochemistry tests mainly include gastrin(GAS), stress related hormone, peroxidatic reaction and the ratio of immune cells.

Interventions

PROCEDURELaparoscopic Surgery
DEVICEAcupuncture treatment

Sponsors

Xiaonan Cui
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Weight: 40kg-90kg, male and female. * Diagnosis: imaging, cell and pathology report. * Brain, heart, lung, liver, kidney are at good condition in 2 weeks before surgery. * No conscious obstacle and limbs disability.

Exclusion criteria

* Fainting during acupuncture. * Electrolyte imbalance. * Serious and life-threatening complications after surgery. * In addition, patients taking part in other clinical trials, being treated with other biotherapy or immunotherapy and researchers consider not suitable for clinical subjects for other reasons will be excluded.

Design outcomes

Primary

MeasureTime frame
Number of participants and classification with operation-related adverse events as assessed by CTCAE v4.03.day 1, day 3, day 5, day 7 after surgery

Secondary

MeasureTime frameDescription
The quality of life questionnaire(QLQ).day 1, day 3, day 5, day 7 after surgeryAssessing in 5 grade, mainly include appetite, sleep, pain,etc.
Stress hormone in blood.day 2, day 7 after surgeryEstradiol (female), progesterone (female), testosterone (male)
Immune cell number ratio in blood.day 2, day 7 after surgeryTh1/Th2, Th17/Treg

Countries

China

Contacts

Primary ContactXiaonan Cui, MD, PhD
cxn23@sina.com+8618098876725

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026